UBS analyst AJ Rice lowered the firm’s price target on Pediatrix Medical (MD) to $22 from $23 and keeps a Neutral rating on the shares. The ACA headwind remains a source of uncertainty, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target lowered to $19 from $21 at Deutsche Bank
- Pediatrix Medical Earnings Call Highlights Steady Margin Focus
- Pediatrix Medical price target lowered to $21 from $24 at Truist
- Pediatrix Medical Group: Streamlined Portfolio, Improved Payer Mix, and Margin Expansion Support Buy Rating Despite Volume Headwinds
- Pediatrix Medical reports Q4 adjusted EPS 50c, consensus 54c